Furosemide to Torsemide Dose Conversion
For oral administration, use a 4:1 conversion ratio (40 mg furosemide = 10 mg torsemide); for intravenous administration, use a 2:1 conversion ratio (20 mg IV furosemide = 10 mg IV torsemide).
Oral Conversion
The most recent mechanistic evidence from the TRANSFORM-Mechanism trial 1 definitively demonstrates that a 4:1 dose equivalence (approximately 40 mg oral furosemide to 10 mg oral torsemide) results in similar natriuresis. This contradicts the traditional 2:1 conversion that clinicians commonly use. When the 2:1 ratio was employed in clinical practice, torsemide produced substantially greater natriuresis than intended, leading to:
- Mild perturbations in kidney function
- Significant increases in renin, aldosterone, and norepinephrine
- No improvement in plasma volume or body weight despite higher diuretic effect
This finding is supported by older pharmacokinetic data 2 showing comparable 24-hour electrolyte excretion when 40 mg oral furosemide was compared to 10 mg oral torsemide.
Key dosing parameters from FDA labeling:
- Torsemide initial dose for heart failure: 10-20 mg once daily 3
- Furosemide initial dose for edema: 20-40 mg once or twice daily 4
- Maximum torsemide dose: 200 mg daily 3
- Maximum furosemide dose: 600 mg daily 4
Intravenous Conversion
For IV administration, use a 2:1 ratio (20 mg IV furosemide = 10 mg IV torsemide). This is based on:
- Multiple studies in renal failure patients showing 1:1 potency after IV administration 5
- Clinical trial data demonstrating that 20 mg IV torsemide produces comparable effects to 40 mg IV furosemide in acute heart failure 6
- FDA labeling indicating 40 mg IV furosemide as standard initial dose 7 versus 10-20 mg for oral torsemide 3
IV furosemide administration specifics 7:
- Initial dose: 20-40 mg IV given slowly over 1-2 minutes
- For acute pulmonary edema: 40 mg IV initially, may increase to 80 mg if inadequate response
- High-dose continuous infusion: maximum rate 4 mg/min
Critical Pharmacokinetic Differences
Despite traditional teaching, torsemide offers no meaningful pharmacokinetic advantages over furosemide 1:
- Kidney bioavailability was actually lower with torsemide (17.1%) versus furosemide (24.8%)
- Duration of action was longer with furosemide for both kidney drug delivery and natriuresis
- Oral bioavailability of torsemide is higher (90%) but this does not translate to superior clinical outcomes
Common Pitfalls to Avoid
Do not use the traditional 2:1 oral conversion - this results in excessive diuresis with torsemide, triggering neurohormonal activation and worsening kidney function without improving volume status 1
Do not assume torsemide is superior - The TRANSFORM trial showed no difference in clinical outcomes between the two agents 1, 8
Monitor for acute kidney injury with torsemide - Recent real-world data shows torsemide is associated with increased risk of acute kidney injury (HR 1.12) compared to furosemide 8
Adjust for route of administration - The conversion ratio differs substantially between oral (4:1) and IV (2:1) routes
Practical Algorithm
When converting from furosemide to torsemide:
Oral: Divide total daily furosemide dose by 4
- Example: 80 mg furosemide daily → 20 mg torsemide daily
IV: Divide furosemide dose by 2
- Example: 40 mg IV furosemide → 20 mg IV torsemide
When converting from torsemide to furosemide:
Oral: Multiply torsemide dose by 4
- Example: 20 mg torsemide daily → 80 mg furosemide daily
IV: Multiply torsemide dose by 2
- Example: 20 mg IV torsemide → 40 mg IV furosemide
Monitor urine output, daily weights, electrolytes, and renal function within 24-48 hours after any conversion to ensure appropriate diuretic response 4, 9.